INTRODUCTION
Neuroendocrine tumors (NETs) are rare neoplasms, with an incidence of between 2 and 9.3 per 100,000 persons per year. 1 They represent a heterogeneous group of tumors arising from neuroendocrine cells of the diffuse endocrine system, which occur most frequently in the gastrointestinal tract and bronchopulmonary system. 2 Neuroendocrine neoplasms often are associated with fibrosis, which may develop locally or at distant sites.
Carcinoid heart disease (CHD) affects up to 40% of patients with carcinoid syndrome (classically defined as the triad of cutaneous flushing, diarrhea, and bronchospasm) and is characterized by the development of fibrotic endocardial plaques and typically right-sided heart valve dysfunction, although approximately 10% of patients also may have left-sided valvular involvement. 3 CHD can progress to heart failure, which is associated with considerable morbidity and may be the cause of death in up to 40% of affected individuals if left untreated. 4 In a series from the Mayo clinic, the 3-year survival rate for patients with CHD was 31% compared with 68% for those without echocardiographic evidence of cardiac involvement. 5 Mesenteric fibrosis is a hallmark of small bowel NETs, and may occur in up to 50% of cases. 6, 7 It commonly is detected radiologically and often has a characteristic appearance of a mesenteric mass with linear soft tissue opacities radiating outward in a "wheel spoke" pattern associated with distortion of the surrounding tissues. Calcification can be present in the mesenteric mass. 6 The number and thickness of radiating strands detected on imaging has been shown to correlate with the degree of fibrosis detected histologically. 8 Mesenteric fibrosis may lead to bowel ischemia due to impingement of the mesenteric vessels in approximately 10% of affected patients and occasionally kinking of the small intestine, resulting in bowel obstruction. 7 It also can cause venous ischemia due to superior mesenteric vein involvement, ultimately resulting in malnutrition and cachexia. Compromise of the mesenteric vasculature can lead to ascites, and extensive involvement often may render surgical resection technically challenging or impossible. 9 The heavy mass of mesenteric lymph nodes also may predispose toward volvulus. 7 Apart from being associated with considerable morbidity, mesenteric fibrosis also is a poor prognostic factor for survival. 7, 10 Other less commonly encountered fibrotic reactions can occur in patients with NETs, such as retroperitoneal fibrosis, which can lead to obstructive uropathy 7, 11 ; scleroderma 12 ; pleural disease 13 ; cryptogenic fibrosing alveolitis 14 ; fibrosis of the bladder 15 ; and elastic vascular sclerosis causing intestinal infarction. 16 Although the association between NETs and fibrosis has been recognized for a long time, to the best of our knowledge the underlying biology of this relationship remains poorly understood. 15, 17 The elucidation of the pathogenesis of fibrosis is of critical importance for the identification of appropriate therapeutic targets and the development of specific strategies for the prevention and treatment of its complications. This article reviews the existing literature regarding the pathophysiology of fibrosis in patients with NETs.
MATERIALS AND METHODS
We conducted a literature search of the MEDLINE database from its inception to June 18, 2017 , for relevant articles regarding the pathophysiology of fibrosis in patients with NETs using the keywords "carcinoid" or "neuroendocrine tumor" AND "fibrosis," "serotonin," "growth factor," or "desmoplasia." We included original research articles (basic research, animal and clinical studies), as well as review articles and case reports/case series relevant to the topic. We excluded: 1) articles that did not focus on NETs; 2) articles related to NETs but without a substantial focus on fibrosis; 3) articles related to NETs with some relevance to fibrosis but no considerable focus on its pathogenesis; and 4) articles not written in or translated into English. Reference lists from studies selected by the electronic search were reviewed manually to identify further relevant articles. The quality and strength of the results were considered, with more emphasis placed on systematic reviews and well-designed original research studies. Case reports and case series were included if clinically relevant.
RESULTS
A large number of results were returned for each of our searches, leading to a total of 20,523 records (in more detail, "carcinoid and fibrosis" led to 182 records, "carcinoid and growth factor" led to 728 records, "carcinoid and serotonin" led to 1331 records, "carcinoid and desmoplasia" led to 187 records, "neuroendocrine tumor and fibrosis" led to 718 records, "neuroendocrine tumor and growth factor" led to 14,946 records, "neuroendocrine tumor and serotonin" led to 1673 records, and "neuroendocrine tumor and desmoplasia" led to 758 records). After removing duplicates, a total of 17,334 records were screened by title and abstract based on our selection criteria, leaving 98 articles for full-text assessment, 81 of which were included in the final review. A manual search of the bibliographies of the selected articles was performed and 61 additional articles also were considered relevant, resulting in a total of 142 pertinent articles (31 basic research studies, 16 animal studies, 46 clinical studies, 7 case reports/case series, 2 letters, and 40 reviews) (Fig. 1 ). Of these, 10 articles were considered for the "tumor microenvironment" section, 82 for the "serotonin" section, 45 for the "growth factor" section, and 12 for the "kinins and other peptides" section (7 articles were referenced twice in different sections).
Tumor Microenvironment
The tumor microenvironment recently has been recognized as a critical determinant of neoplastic evolution due to the realization that tumors are not simply masses of neoplastic cells, but instead represent complex tissues consisting of extracellular matrix (ECM) and a plethora of cells (neoplastic cells, cancer-associated fibroblasts/myofibroblasts, inflammatory cells, and capillary-associated cells) with functional interactions. 18 This dynamic microenvironment may influence tumor cell growth, survival, and metastatic potential, thus playing a key role in tumor progression. 19 It also can be involved in the development of tumor heterogeneity in certain cancers. 20 The complex interplay between tumor cells and cancer-associated fibroblasts is largely responsible for the pathological ECM remodeling and desmoplasia observed in various types of cancer. 21, 22 Tumor desmoplasia may facilitate tumor cell migration and invasion in certain types of malignancies, such as breast cancer and squamous cell carcinoma, and can promote tumor proliferation and chemotherapeutic resistance in malignant tumors, such as hepatocellular carcinoma. Therefore, it is considered a poor prognostic factor in some cancers. 21, 22 The elucidation of these complex and dynamic interactions between tumor cells and stroma ideally requires functional studies of the tumor microenvironment. To the best of our knowledge, there are few such studies in the field of NETs. Svedja et al investigated the crosstalk between tumor cells and fibroblasts in a coculture model using the KRJ-I (small intestinal NET cell line 23, 24 ) and human embryonic kidney (HEK) 293 (HEK293) cells (human embryonic kidney cell line), an experimental model essentially simulating the microenvironment of a small intestinal NET associated with fibrosis ( Fig. 2) . In this Transwell coculture system (which is representative of a nondirect coculture system to evaluate paracrine effects), the addition of a specific 5-hydroxytryptamine receptor 2B (5-HT 2B ) receptor antagonist in the tumor cellcontaining compartment inhibited the proliferation of KRJ-I cells and significantly reduced serotonin (5-hydroxytryptamine ) release and profibrotic/angiogenetic Neuroendocrine Tumors and Fibrosis/Laskaratos et al Cancer December 15, 2017 factor (transforming growth factor b1 [TGF-b1], connective tissue growth factor [CTGF] , and fibroblast growth factor 2 [FGF2]) synthesis. It is interesting to note that cell proliferation and transcripts of these factors also decreased in cocultured HEK293 cells, despite the absence of a 5-HT 2B receptor on this cell line. The authors suggested that the KRJ-I-derived 5-HT in this coculture model was responsible for the cellular crosstalk between tumor cells and HEK293 cells (which are known to express 5-HT 2A/C receptors). 25 In a separate study, Kidd et al isolated intestinal stellate cells from a single patient with a small intestinal NET associated with peritoneal fibrosis. These cells were cultured for 5 to 7 days. Stimulating these cells with TGF-b1 (a growth factor known to be expressed in many gastrointestinal NETs 26 ) significantly increased CTGF messenger RNA (mRNA) expression compared with unstimulated cells. CTGF is a known mediator of fibrosis and therefore this experiment demonstrated that the interaction between tumor and stellate cells plays a crucial role in fibrogenesis. 27 
Serotonin
Serotonin (5-HT) is synthesized mainly in the enterochromaffin cells of the gastrointestinal tract and in enteric neurons from the essential amino acid tryptophan. 28 Platelets become loaded with serotonin as they pass through the intestinal circulation, with up to 95% of circulating serotonin stored in platelets. Serotonin in tissues is rapidly metabolized to 5-hydroxyindole acetic acid (5-HIAA) by monoamine oxidase and excreted in the urine. The gut and central nervous system also possess an inactivating mechanism, the serotonin reuptake transporter, which plays an important role in terminating transmitter action. 5-HT effects are mediated through its binding to 5-HT receptors and 7 types or families with multiple subtypes currently have been identified by a combination of pharmacological techniques and molecular cloning (termed 5-HT1 through 5-HT7). With the exception of the 5-HT3 receptor, a ligand-gated ion channel, serotonin receptors are a group of membrane-bound G-protein coupled receptors that activate various intracellular pathways. 29 These receptors demonstrate variability in expression and a different distribution in various organs. 28 5-HT is a key mediator of gastrointestinal function and motility and plays a major role in the pathophysiology of many gastrointestinal diseases. 30, 31 In addition, there is a strong evidence base implicating the activation of 5-HT 2B receptors in the pathogenesis of CHD, but 5-HT also appears to play a role in the development of other fibrotic conditions associated with NETs. There are several lines of evidence suggesting that 5-HT is involved in carcinoidrelated fibrosis.
Experiments in cell cultures
5-HT has mitogenic effects in fibroblasts, [32] [33] [34] [35] mesangial cells, 36 smooth muscle cells, 37, 38 endothelial cells, 39 and osteoblasts. 40, 41 It also is mitogenic in carcinoid tumor cells, as demonstrated in experimental studies using Mastomys natalensis carcinoid tumor cells and bronchopulmonary (NCI-H720 and NCI-H727) and small intestinal (KRJ-I) NET cell lines. 35, 42 It also appears to be an important mediator in the crosstalk of tumor and stromal cells in a coculture model simulating the microenvironment of a fibrotic small intestinal NET. 25 In addition, in vitro experiments have suggested that 5-HT contributes to fibrin resistance to fibrinolysis, thereby providing further evidence for the role of 5-HT in fibrogenesis. 43 
Role in mesenteric fibrosis
The nidus of tumor growth within the mesentery is believed to be a lymph node, but hematogenous spread directly to the mesentery also has been suggested as a separate mechanism of metastasis. 8, 44 A fibroblastic reaction is known to occasionally develop around the metastatic deposit and the previously described coculture model of KRJ-I and HEK293 cells suggests a role for serotonin in the pathophysiology of this process. 25 These findings also are supported by a clinical study of 52 patients with midgut NETs, which demonstrated that elevated platelet 5-HT correlated with the presence of a mesenteric mass. 45 In addition, a recent study demonstrated a significant association of mesenteric fibrosis with elevated urinary 5-HIAA levels, suggesting a potential causal relationship. 46 However, a smaller study of 31 patients (17 with and 14 without intra-abdominal fibrosis) failed to demonstrate a correlation between fibrosis and mean or peak urine 5-HIAA levels, but the authors acknowledged the small study size and the lack of data regarding the "area under the curve" for urine 5-HIAA (reflecting levels in relation to time) as limitations. 6 
Role in pancreatic fibrosis
A small number of clinicopathological studies have described an association between prominent stromal fibrosis in pancreatic NETs (PNETs) and 5-HT expression. The so-called "sclerosing variant" of PNET is rare, accounting for <15% of PNETs, and the associated fibrotic reaction usually involves the main pancreatic duct, resulting in ductal stenosis and upstream duct dilatation and/or pancreatic atrophy. This variant has distinct pathologic features and biomarker expression profiles, and a significantly higher percentage of these tumors are serotonin-producing neoplasms compared with nonfibrotic PNETs. [47] [48] [49] [50] [51] The sclerosing PNETs usually demonstrate infiltrative growth patterns and are associated with more advanced stages of disease compared with nonsclerosing tumors. 48 
Role in cardiac fibrosis
Several experimental animal studies have demonstrated that 5-HT can induce cardiac fibrosis and valvulopathy, therefore suggesting that it may play a critical role in the development of CHD. [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] A summary of these studies is provided in Table 1 . histopathology Animals in group 2 had significantly higher heart weights compared with those in groups 1 and 3, suggesting that terguride may prevent 5-HT-induced heart disease; right-sided echocardiographic changes were only seen in group 2; no consistent histopathological differences were found in valves between groups In addition, a combination of prospective and retrospective clinical studies have implicated 5-HT and its metabolite 5-HIAA in the pathogenesis of CHD and a threshold effect has been suggested with urinary 5-HIAA levels >100 mg. 5, [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] A summary of what we believe to be the most important studies is provided in Table 2 . 5, [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] Further evidence for the role of serotoninergic pathways in the development of CHD comes from the elucidation of the pathophysiology of drug-induced valvular heart disease. Antimigraine ergot alkaloid agents (ergotamine and methysergide), appetite suppressants (fenfluramine and dexfenfluramine), and ergot-derived dopamine agonists used for the treatment of Parkinson disease and restless leg syndrome (pergolide and cabergoline) have been associated with the development of mainly left-sided valvular abnormalities that closely resemble carcinoid-related valvulopathies, thereby raising suspicion for a common pathophysiologic mechanism with CHD. 3, [75] [76] [77] [78] [79] [80] [81] [82] [83] Methysergide and its active metabolite methylergonovine also are known to induce retroperitoneal, myocardial, aortic, and pleuropulmonary fibrosis. [84] [85] [86] All the implicated drugs (or their metabolites) have been shown to have high affinity for and to be partial or full agonists of the 5-HT receptor subtype 5-HT 2B (5-HT 2B R). [87] [88] [89] Although to the best of our knowledge the precise signaling pathways leading to valvulopathy are unknown, 5-HT 2B Rs are known to activate various mitogenic pathways, such as the phosphorylation of Src kinase and extracellular regulated kinases (ERK), with a final common pathway that may include phosphorylation of retinoblastoma protein leading to cell division (Fig.  3) . 90, 91 In fact, 5-HT 2B R agonists can mediate fibroblast mitogenesis in vitro, suggesting that circulating serotonin may directly stimulate the proliferation of valve interstitial cells and induce heart valve fibroplasia. 92, 93 The 5-HT 2B R also mediates important trophic functions in cardiovascular morphogenesis. 94, 95 Overexpression of 5-HT 2B Rs in transgenic mice induced ventricular hypertrophy, 94 whereas ablation of 5-HT 2B Rs led to severe cardiac hypoplasia and ventricular dilatation associated histologically with loss of myocardial organization, cardiomyocyte degeneration, and myofibrillar disarray. 95, 96 In an in vivo model of drug-induced valvular heart disease, the administration of intraperitoneal injections of pergolide induced aortic, mitral, and pulmonary regurgitation in rats with histological evidence of diffusely thickened and myxoid valves. 97 Cyproheptadine, a 5-HT 2B antagonist, effectively prevented toxic valvulopathy in this animal model and this therapeutic benefit was found to be associated with downregulation of 5-HT 2B Rs in interstitial and endothelial valvular cells. This study provided further evidence of the involvement of 5-HT 2B R in the pathogenesis of serotoninergic drug-induced valvulopathy, with potentially important clinical implications for its prevention. 98 Furthermore, a link recently was found between serotoninergic pathways and oxidative stress that could act as a mediator of valvular fibrosis. Oxidative stress is defined as the imbalance between the production of reactive oxygen species (ROS) and the ability of cells to produce an effective antioxidant response. Oxidative stress has been implicated in the development of many fibrotic diseases, including idiopathic pulmonary fibrosis, 99 liver fibrosis, 100 kidney fibrosis, 101 skin fibrosis, 102 and tissue remodeling after myocardial infarction. 102 Evidence had demonstrated that ROS also could be involved in the pathogenesis of CHD. Incubation of homogenates of human heart valves and proximal segments of pulmonary artery with serotonin significantly increased levels of superoxide (O 2 -). ROS were released as a byproduct during metabolism of serotonin by monoamine oxidase A, which normally is present in a variety of tissues, including heart, blood vessels, brain, kidney, and liver. 103 Other experimental studies have shown that oxidative stress is involved in the development of valvular heart disease (calcific aortic valvular stenosis) in humans. 104 Therefore, serotonin could contribute toward the pathogenesis of CHD by inducing monoamine oxidase A-dependent oxidative stress in human heart valves, which may cause valvulopathy.
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Growth Factors
Several growth factors have been investigated for their potential role in the development of fibrosis in NETs. A summary of what to our knowledge are the most important studies is provided in Table 3 . 26, 27, 71, [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] Transforming Growth Factor b
The transforming growth factor b (TGF-b) family is divided into 2 general branches (the bone morphogenetic protein [BMP]/growth differentiation factor [GDF] branch and the TGF-b1, TGF-b2, TGF-b3, and their latent forms/activin/lymph node branch), whose members regulate multiple cellular processes, including cell division, differentiation, migration, and programmed cell death and therefore have key roles in development and carcinogenesis. [119] [120] [121] [122] Mutations or alterations in the TGF-b signaling pathway may play a substantial role in carcinoid tumor development, which has been shown in Review Article experimental studies using small intestinal (KRJ-I) and pancreatic (BON) NET cell lines.
123,124
Chaudhry et al demonstrated that in a series of 30 gastroenteropancreatic (GEP) NETs, the majority of tumor cells expressed all 3 isoforms of TGF-b and stromal cells significantly expressed TGF-b2 and latent TGF-bbinding protein (LTBP). TGF-b type 2 receptor immunoreactivity was observed mostly in the stromal cells, suggesting that TGF-b might play an important role in the interaction of tumor and stromal cells and possibly stimulate matrix production in these tumors. 26 TGF-b may play a critical role in fibrogenesis due to its known ability to stimulate collagen synthesis. 17, 125, 126 Beauchamp et al demonstrated that the culture medium of BON cells (derived from a peripancreatic lymph node that contained a metastatic deposit of a PNET) contained all 3 mammalian types of TGF-b and that it could stimulate the proliferation of mouse (AKR-2B) fibroblasts. 105 TGF-b also has been implicated in the development of CHD. In a small clinicopathological study of 9 patients with CHD, TGF-b1 and TGF-b3 were found to be immunohistochemically present in the fibroblasts of carcinoid plaques, whereas LTBP was present mainly in the extracellular space. In contrast, sections from unaffected control heart tissue contained few fibroblasts, with only weak or no immunostaining for TGF-b1, TGF-b2, TGFb3, and LTBP. 106 However, in another study, plasma levels of TGF-b were not found to be associated with the presence of CHD, but the investigators acknowledged that the levels of growth factors in the systemic circulation may not be an accurate reflection of local levels within the carcinoid plaques. 71 A link has been suggested between serotonin and TGF-b signaling pathways that also may play a key role in the pathophysiology of CHD. Experimental studies using cultured sheep aortic valve interstitial cells demonstrated that serotonin induced TGF-b1 mRNA production and increased TGF-b1 activity via 5-HT 2A receptor activation. Serotonin also increased collagen biosynthesis by sheep aortic valve interstitial cells, which was inhibited by an anti-TGF-b antibody, thus indicating the specificity of serotonin stimulation by TGF-b1. 127, 128 In addition, clinicopathological investigation of human carcinoid and normal valve cusps using immunohistochemical techniques demonstrated that staining for the latent form of TGF-b1 (LAP TGF-b1) and alpha smooth muscle actin (a marker of activated myofibroblasts) was more prominent in carcinoid compared with control valves. Conceivably, the greater amounts of LAP TGF-b1 found in carcinoid cusps compared with controls are likely to reflect upregulation of TGF-b because of serotonin. Abbreviations: a-SMA, alpha smooth muscle actin; aFGF, acidic fibroblast growth factor; bFGF, basic fibroblast growth factor; BMP4, bone morphogenetic protein 4; CHD, carcinoid heart disease; CTGF, connective tissue growth factor; EGFR, epidermal growth factor receptor; ELISA, enzyme-linked immunoadsorbent assay; FGF, fibroblast growth factor; GI, gastrointestinal; LTBP, latent TGF-b-binding protein; LV, right ventricular; mRNA, messenger RNA; NET, neuroendocrine tumor; PDGF, platelet-derived growth factor; PNET, pancreatic neuroendocrine tumors; RT-PCR, reverse transcriptase-polymerase chain reaction; RV, right ventricular; SI, small intestinal; TGF-a, transforming growth factor a;
TGF-b, transforming growth factor b; VEGF, vascular endothelial growth factor; VEGF-R2, vascular endothelial growth factor receptor 2.
Another member of the TGF family, activin A, has been shown to be an independent predictor of CHD, although there was no significant difference in activin A levels noted between patients with early versus advanced disease. Activin A levels 0.34 ng/mL were found to have 87% sensitivity and 57% specificity for detecting CHD. Immunohistochemically, activin A was strongly expressed in tumor tissue as well as fibrotic plaques, although no control tissue was used for comparison. 107 BMP4, another member of the TGF family, may be implicated in the pathogenesis of mesenteric angiopathy (defined as vascular sclerosing changes involving all layers of the vessels) in midgut carcinoids. In a small study, BMP4 expression was found to be significantly higher in midgut tumors with angiopathy compared with those without, independent of the presence or absence of mesenteric sclerosis. 108 
Connective Tissue Growth Factor
CTGF/CCN2 is a downstream mediator of TGF-b1 in fibroblastic cells, and plays a substantial role in wound repair, tumorigenesis, and fibrosis.
2,129-131 CTGF acts as a mitogenic growth factor that regulates enterochromaffin-like cell proliferation in the Mastomys animal model and also can promote the development of gastrin-autonomous gastric carcinoids. 132 In a study of a heterogeneous group of NETs, CTGF was found to be more prevalent in small intestinal NETs (>50% of tumor cells demonstrated intense CTGF immunoreactivity) compared with pancreatic, rectal, and bronchial NETs. Immunoreactive cells were adjacent to areas with increased fibrovascular stroma that expressed alpha smooth muscle actin, suggesting that CTGF may play a critical role in myofibroblast-mediated fibrosis associated with ileal carcinoids. 109 These findings were supported by another study that demonstrated significantly higher mRNA levels of CTGF and TGF-b1 in small intestinal carcinoid tumors compared with normal mucosa and gastric (nonfibrotic) carcinoids. 27 Similarly, higher levels of CTGF immunostaining were observed in small intestinal NETs with clinically and histologically documented evidence of peritoneal fibrosis compared with nonfibrotic gastrointestinal carcinoids and normal mucosal tissue. Serum CTGF levels were higher in patients with small intestinal NETs compared with patients with gastric carcinoids and control patients. 27 In another study of 69 patients with midgut NETs, elevated plasma CTGF levels were associated with right ventricular dysfunction and right-sided valvular regurgitation, although there was no significant association observed with the presence of CHD using defined criteria. Plasma CTGF 77 lg/L was predictive of right ventricular dysfunction, with 88% sensitivity and 69% specificity. 110 CTGF may be a promising therapeutic target. Anti-CTGF single-chain variable fragment antibodies attenuated bleomycin-induced pulmonary fibrosis in mice, and neutralizing monoclonal antibodies to CTGF attenuated ventricular remodeling in animal models of dilated cardiomyopathy and pressure overload-induced heart failure. 133, 134 However, to the best of our knowledge, there are no therapeutic trials assessing the antifibrotic effect of antibodies against CTGF in patients with NETs.
Platelet-derived growth factor
Platelet-derived growth factor (PDGF) is a major mitogen for mesenchymal-derived cells and is composed of 4 isoforms (PDGF-A, PDGF-B, PDGF-C, and PDGF-D), which may form homodimers and heterodimers (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD). Two distinct receptor types, a receptors and b receptors, have been characterized to date. The classic targets for PDGF effects (eg, fibroblasts and smooth muscle cells) have both a receptors and b receptors, whereas other cell types (eg, oligodendrocyte progenitor cells) have only a receptors and others (eg, rat brain capillary endothelial cells) have only b receptors. 111 PDGF production by malignant cells is known to lead to the recruitment of cancer-associated fibroblasts in skin cancer, thereby promoting the formation of a thicker fibrous capsule surrounding the tumor, 135 and has been implicated in the development of fibrosis in systemic scleroderma, chronic liver disease, and renal disorders. The elucidation of the extracellular and intracellular signaling events involved in PDGF pathways in these conditions has led to the development of PDGF antagonists, which act as effective antifibrotic agents in culture and in some animal models, although their clinical use has been limited by their lack of specificity and side effect profile. [136] [137] [138] There is evidence that PDGF is involved in fibrogenesis associated with NETs, although clinical research in this area has lagged behind other fibrotic conditions, such as liver fibrosis and scleroderma. Chaudhry et al demonstrated that in a heterogeneous group of GEP NETs, PDGF was expressed on tumor cells and the stroma in 70% of cases. PDGF a receptors were present on tumor cells and occasionally on stromal cells, whereas PDGF b receptors were observed only in the stroma. The authors hypothesized that PDGF may be involved in the stimulation of stromal cell growth through a paracrine and possibly autocrine mechanism, suggesting a role in fibrosis. In addition, PDGF synthesized by the surrounding stromal component of these tumors may stimulate tumor growth in a paracrine manner. 111, 112 In another study of a heterogeneous group of mostly midgut and pancreatic NETs, stromal cells adjacent to tumor cells stained more strongly positive for PDGF b receptors compared with stromal cells that were distant from tumor cell clusters. The authors suggested that carcinoid tumor cells may induce expression of PDGF b receptors on adjacent stromal cells, which may contribute toward the pronounced fibrosis surrounding the tumor tissue. 113 
Insulin-like growth factor
Insulin-like growth factors (IGFs) (IGF-1 and IGF-2) have structural homology with proinsulin and have biological effects similar to those of insulin. Their effects are mediated via specific receptors (type I and type II) and they are considered to play an important role in growth regulation of NETs. [139] [140] [141] Nilsson et al demonstrated the presence of IGF-1 in 11 consecutive cases of midgut carcinoids and IGF-1 receptors in approximately one-half of the tumors. Stimulation of cultured tumor cells with IGF-1 induced proliferation, suggesting that this growth factor may act as an autocrine stimulator of carcinoid tumor growth. 142 IGF-1 and IGF-2 also are known to stimulate cell replication in primary chick embryo fibroblast cultures, passaged human fibroblasts, and fibroblast lines of mammals, although they are less potent than PDGF. 143 Therefore, they may have a role in the development of fibrosis in NETs.
TGF-a/epithelial growth factor receptor TGF-a, a peptide structurally related to epithelial growth factor (EGF), is overexpressed in NETs and mediates its effects by binding to the EGF receptor (EGFR). It is known to act as a mediator of angiogenesis, 144 tumor cell proliferation, 145, 146 and fibrosis in NETs. In a study of a heterogeneous group of GEP NETs, TGF-a was expressed in approximately 90% of cases, but EGFR expression was significantly higher in the tumor and stromal component of midgut compared with pancreatic neuroendocrine neoplasms. The authors suggested that this difference may account for the more pronounced fibrosis observed in midgut carcinoids. 114 They also hypothesized that TGF-a produced by tumor cells could bind to EGFR expressed by stromal and tumor cells and contribute to the associated desmoplastic reaction and neovascularization, perhaps by a paracrine mechanism, and to tumor cell growth by an autocrine mechanism.
Fibroblast growth factor
The FGF family includes a large number of growth factors that regulate multiple developmental processes 147 and have been implicated in the development of fibrosis in gastrointestinal NETs. In a small study of patients with gastric NETs, 10 of 17 patients with a type 3 gastric NET demonstrated positive immunostaining for basic FGF and some of those also were associated with diffuse stromal fibrosis, suggesting a possible functional role for basic FGF secreted by tumor cells in the proliferation of stromal fibroblasts or other mesenchymal cell types. 115 In another study of a heterogeneous group of 41 gastrointestinal NETs, a positive correlation was found between acidic FGF and the amount of fibrous stroma, suggesting that acidic FGF might be involved in the proliferation and activity of stromal fibroblasts. 116 However, in a small study of 37 patients with carcinoid syndrome, 9 of whom had CHD, circulating levels of FGF were not found to be associated with cardiac fibrosis. 71 
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) has 2 receptors (VEGF-R1 and VEGF-R2) and is an important proangiogenic factor. VEGF-R2 is responsible for the proliferative response of endothelial cells to VEGF, whereas VEGF-R1 is responsible for vascular tabulation and maturation. In a small series of 12 patients with pulmonary tumorlets and neuroendocrine cell hyperplasia, the tumorlets were located in hypervascularized areas associated with fibrosis, which ranged in severity from mild to intense. These patients demonstrated significantly higher expression of VEGF and VEGF-R2 in endothelial cells and significantly increased VEGF-R1 expression in bronchial epithelial and endothelial cells compared with a control group of patients with normal lungs. This may indicate the involvement of VEGF in the development of fibrosis around tumorlets. However, the majority of subjects in the patient group had pulmonary diseases such as emphysema, bronchiectasis, and tuberculosis, which may be associated with pulmonary fibrosis and act as a confounding factor. 117 A case report of a pulmonary carcinoid tumorlet associated with fibrosis also demonstrated strong production of TGF-b1 and VEGF by tumor cells, thereby suggesting the possible involvement of these growth factors in the fibrotic process. 118 
Kinins and Other Peptides
Kinin peptides are known to be released into the circulation during flushing episodes in patients with carcinoid syndrome and may act as fibrotic mediators. 148, 149 Bradykinins are potent in altering endothelial permeability and may play a role in the production of carcinoid heart lesions. 150 Tachykinins (substance P, substance K) are mitogenic in arterial smooth muscle cells, human skin, and mouse (3T3) fibroblasts. 151, 152 In a Swedish study of 68 patients with midgut NETs and carcinoid syndrome, the plasma levels of the tachykinins neuropeptide K and substance P were significantly higher in those subjects with severe right heart disease compared with those with mild or no changes. 67 Similarly, in a large multicenter UK study of 187 patients with metastatic NETs in which a panel of biomarkers were evaluated as predictors of CHD, neurokinin A levels were found to be significantly higher in patients with CHD compared with those without cardiac involvement. 74 In a small series of 28 cases of medullary thyroid carcinoma (which is derived from the thyroid parafollicular calcitonin-secreting cells or C cells), there was a significant correlation noted between the degree of desmoplasia determined histologically and the expression of fibroblast activation protein a (FAP-a) (a type II serine protease capable of degrading gelatin and type I collagen) and tenascin C (TN-C) (an extracellular matrix glycoprotein). The extent of this desmoplastic stromal reaction also was shown to correlate with the incidence of lymph node metastases. FAP-a is known to function as an active serine protease, and may be involved in direct remodeling of the ECM during cancer invasion. TN-C is upregulated in many human cancers, and this increased expression also has shown correlation with increased invasiness. 153 In a larger study of 100 cases of medullary thyroid carcinoma, the degree of desmoplasia correlated significantly with expression of TN-C, as well as the hypoxia-associated proteins hypoxia-inducible factor 1a (HIF-1a) and carbonic anhydrase 9 (CAIX), suggesting that focal tumor hypoxia may trigger remodeling of the ECM. 154 Another peptide that has been implicated in the development of dense fibrosis around tumorlets is the gastrin-releasing peptide (GRP). In a case report of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (NECH) with a central and peripheral typical bronchial NET and multiple tumorlets associated with fibrosis, the preoperative serum pro-GRP level was high but returned to normal after lobectomy, indicating that GRP was produced and secreted by carcinoids, tumorlets, or NECH lesions. Immunohistochemical analysis of 17 neuropeptides and a trophoblastic peptide (human gonadotrophin alpha) demonstrated intense expression of GRP in carcinoids, tumorlets, and NECH lesions, suggesting that this peptide could be involved in the development of local fibrosis in a paracrine manner. 155 Finally, NET cells can produce many other amines and polypeptides, including prostaglandins and cytokines. 91 Although to the best of our knowledge their role in the development of NET-related fibrosis has not been investigated to date, prostaglandins and interleukins are known to play a role in the development and maintenance of chronic inflammation and to act as profibrotic molecules. 156, 157 Pathway Crosstalk and Other Considerations
The role of the various factors known to be involved in NET-related fibrogenesis has been described in separate sections to allow for a more structured presentation and summary of the literature. However, it would be naive to suppose that these factors act independently via discrete signaling pathways. In contrast, there is a growing body of evidence to suggest that these factors interact with each other, and the complex crosstalk between signaling pathways is largely responsible for the complex nature of fibrosis and the difficulty in establishing effective antifibrotic therapies. Growth factor signaling pathways share many downstream signaling molecules and may act synergistically or antagonistically to each other. The crosstalk between pathways also may occur at the level of receptorligand interactions. 158, 159 For example, CTGF binds its receptor CTGFR, but also may bind IGF receptors. In addition, activation of CTGFR augments both IGF receptor and EGFR signaling pathways, which in turn induce collagen production and cell proliferation. 141 It also is interesting to note that patients with NETs often have very similar clinical presentations in terms of tumor site, functionality, and stage of disease but only some of these individuals develop fibrotic complications during the course of their illness. In addition, despite the known central role of serotonin in the development of CHD, >50% of patients with elevated circulating serotonin levels paradoxically do not develop cardiac fibrosis. 90 It may be that the development of fibrosis depends on the balance between profibrotic and antifibrotic factors and the crosstalk among multiple signaling pathways rather than a single or a few factors considered in isolation.
It also is apparent from the current review that although many studies have focused on the pathogenesis of CHD, less emphasis has been placed on the pathophysiology of mesenteric fibrosis, which to our knowledge currently is poorly understood. The limited evidence that is available suggests that 5-HT, TGF-b, and CTGF signaling pathways appear to play a role in the development of mesenteric fibrosis. 25, 26, 45, 46 However, these factors most likely are produced by the tumor cells that metastasize to the mesentery and possibly cancer-associated fibroblasts and appear to act locally to produce a fibrotic reaction, unlike CHD, in which circulating levels of these factors are more important. Further research is needed in this area to improve our understanding of the underlying mechanisms of mesenteric fibrogenesis.
Many factors have been investigated in terms of their potential involvement in NET-related fibrogenesis, but not to the same extent or with the same scrutiny. Serotonin, TGF-b, and CTGF certainly have been explored in more depth, and their association with NET-related fibrosis has in addition been demonstrated in functional (dynamic) studies of the tumor microenvironment. The remaining growth factors generally have been investigated in older studies, mostly using "static" techniques (immunohistochemistry) to establish their possible association with fibrosis, but the lack of functional investigations indicates that a causal relationship cannot be proved with this methodology.
Conclusions
NETs often are associated with diverse fibrotic complications, which can lead to devastating clinical sequelae and cause considerable morbidity and mortality. However, our knowledge of the biologic basis of this relationship is relatively limited. Because to our knowledge there are no established medical therapies for the prevention or regression of fibrosis in patients with NETs, there is an unmet need for meaningful investigations into the pathophysiology of this association. Research in this area has lagged behind in comparison with that for other chronic fibrotic conditions such as liver disease, and there undoubtedly is a lot to be learned from developments in the study of fibrogenesis in other disorders. Unfortunately, NET cell lines that can serve as a model for human cancer have several limitations and may not be widely available or well characterized, and this poses significant challenges in basic science regarding NETs. 160 In addition, compared with other disciplines, there is a lack of suitable animal models, which generally are limited to a few in vivo xenograft mouse models using NET cell lines. 160 Therefore, it is difficult to study the mechanisms of fibrogenesis and, more important, to investigate the effect of antifibrotic agents in preclinical animal studies. Despite these challenges, there undoubtedly are many exciting opportunities for future research in the field of fibrosis in NETs. The evaluation and development of noninvasive biomarkers of fibrosis could have important clinical implications. Such biomarkers potentially could predict the development of fibrosis at an early preclinical stage or help to stratify patients into different categories of risk of fibrotic complications, perhaps alongside other clinical information. This would be important not only for prognostication purposes, but also for targeting patients at highest risk of poor outcomes with experimental antifibrotic therapies. The investigation of epigenetic changes in NETs as a driver of fibrogenesis is another promising area for future research. Common epigenetic alterations (DNA methylation, posttranscriptional modifications of histones, and noncoding RNAs) are known to contribute toward the pathogenesis of fibrosis in many chronic fibrotic disorders, such as systemic scleroderma and cardiac, kidney, and pulmonary fibrosis. 161 The measurement of cell-free DNA methylation modifications in the blood also has been suggested as a potentially useful novel biomarker for the stratification of liver fibrosis associated with nonalcoholic steatohepatitis, although its role as a liquid biopsy requires further validation. 162 This may be an exciting avenue for future research in NET-related fibrosis. The role of oxidative stress in the development of fibrosis in patients with NETs is another interesting research area that requires further exploration. Although suggestions for study design are beyond the scope of this review, the investigation of variations in gene/ protein expression and epigenetic changes in patients with NETS with and without (or with varying degrees of) fibrosis may be an appropriate research strategy. Other important areas for future study would include functional and dynamic experiments of the tumor microenvironment using appropriate NET cell lines or cancer-associated fibroblasts isolated from human tissue to unravel the complex mechanisms of fibrogenesis at a cellular level. Certainly, the precise details of research protocols will need to vary depending on the specific area of interest in NET fibrogenesis. Finally, therapeutic studies assessing the effect of antifibrotic agents with appropriate coculture models of the tumor microenvironment and available animal models would be of considerable value for translating advances in basic research into clinical practice.
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
Christos Toumpanakis and Martyn Caplin have received honoraria for lectures and advisory board membership and educational grants for the Royal Free NET unit from Novartis and Ipsen and have
